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Abstract
Background: Diagnosis based on prion detection in lymph nodes of sheep and goats can improve
active surveillance for scrapie and, if it were circulating, for bovine spongiform encephalopathy
(BSE). With sizes that allow repetitive testing and a location that is easily accessible at slaughter,
retropharyngeal lymph nodes (RLN) are considered suitable organs for testing. Western blotting
(WB) of brain homogenates is, in principle, a technique well suited to both detect and discriminate
between scrapie and BSE. In this report, WB is developed for rapid diagnosis in RLN and to study
biochemical characteristics of PrPres.
Results: Optimal PrPres detection in RLN by WB was achieved by proper tissue processing,
antibody choice and inclusion of a step for PrPresconcentration. The analyses were performed on
three different sheep sources. Firstly, in a study with preclinical scrapie cases, WB of RLN from
infected sheep of VRQ/VRQ genotype – VRQ represents, respectively, polymorphic PrP amino
acids 136, 154, and 171 – allowed a diagnosis 14 mo earlier compared to WB of brain stem.
Secondly, samples collected from sheep with confirmed scrapie in the course of passive and active
surveillance programmes in the period 2002–2003 yielded positive results depending on genotype:
all sheep with genotypes ARH/VRQ, VRQ/VRQ, and ARQ/VRQ scored positive for PrPres, but
ARQ/ARQ and ARR/VRQ were not all positive. Thirdly, in an experimental BSE study, detection
of PrPres in all 11 ARQ/ARQ sheep, including 7 preclinical cases, was possible. In all instances, WB
and IHC were almost as sensitive. Moreover, BSE infection could be discriminated from scrapie
infection by faster electrophoretic migration of the PrPres bands. Using dual antibody staining with
selected monoclonal antibodies like 12B2 and L42, these differences in migration could be
employed for an unequivocal differentiation between BSE and scrapie. With respect to
glycosylation of PrPres, BSE cases exhibited a greater diglycosylated fraction than scrapie cases.
Furthermore, a slight time dependent increase of diglycosylated PrPres  was noted between
individual sheep, which was remarkable in that it occurred in both scrapie and BSE study.
Conclusion: The present data indicate that, used in conjunction with testing in brain, WB of RLN
can be a sensitive tool for improving surveillance of scrapie and BSE, allowing early detection of BSE
and scrapie and thereby ensuring safer sheep and goat products.
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Background
Transmissible spongiform encephalopathies (TSEs) or
prion diseases are fatal diseases of the central nervous sys-
tem, characterized by long incubation periods before neu-
rological symptoms appear. TSEs were initially described
in sheep as a transmissible disease named scrapie, and in
man, as Creutzfeldt-Jakob disease (CJD), a sporadic dis-
ease with no detectable link between cases. The diseases
can be diagnosed by vacuolation of neurons in the brain
and appearance of a structurally altered form of the host
encoded prion protein (PrP), termed PrPSc. TSEs represent
a unique class of infectious diseases in which PrPSc is con-
sidered to be the transmissible agent [1-3].
TSEs have attracted much attention since bovine spongi-
form encephalopthy (BSE) was first described in the
1980s [4]. The more or less accepted explanation for the
appearance of this condition was the capacity of the
scrapie-like agent to spread to cattle fed with insufficiently
heated remains of ruminants [5]. In the 1990s a new form
of CJD was observed affecting mainly young people [6].
This so-called variant CJD is considered to be caused by
the BSE agent [7] and to have spread by the consumption
of infected food containing residual bovine nervous tis-
sues, although other means of transmission, such as the
use of ruminant-derived substances in medical products,
can not be ruled out. Furthermore, man-to-man transmis-
sions might have occurred subsequently by blood transfu-
sions. BSE is now largely under control, but two recent
reports describing goats with BSE have strengthened the
fear that the BSE agent could again become widespread in
some food animals before being diagnosed [8-10]. In
order to prevent this from happening, the TSEs from live-
stock must be eradicated. For this purpose a number of
programmes are underway.
For eradication of ruminant TSEs in Europe, where BSE
cases have occurred in nearly all member states, control
programmes have been implemented (EU legislation
999/2001 and additions), e.g., the removal of risk materi-
als, active monitoring of slaughtered cattle, sheep and
goats, stamping out of scrapie, and genetic breeding of
sheep towards scrapie and BSE resistant PrPgenotypes.
Active monitoring is possible using brain tissue taken late
in the incubation phase. Early diagnosis of TSEs can assist
in monitoring programs and has potential in sheep and
goats where lymphoreticular tissues generally accumulate
infectivity and aberrant PrP [11-14]. Indeed, until now,
tonsil and other lymphoid tissues have been targets for
preclinical scrapie diagnosis in sheep, making reliable
diagnosis possible in biopsies early during incubation
[15-17]. However, for the diagnosis to be as early as pos-
sible, i.e. in the preclinical stage, diagnostic methods more
rapid than the time consuming microscopic and bioassay
techniques currently employed are required. Such a diag-
nosis should also preferably allow discrimination
between TSE strains like scrapie and BSE, as is described
for Western blotting (WB) methods applied to brain [18-
22].
A very reliable indicator of disease is the presence of
abnormal forms (PrPSc) of prion protein. It is recognized
by immunohistochemistry (IHC) as accumulations of
PrP, or as a partially protease-resistant protein (PrPres). By
WB of PrPres using PrP-specific antibodies, a typical triplet
banding pattern appears, representative of diglycosylated,
monoglycosylated and aglycosyl PrPres moieties, migrat-
ing with apparent molecular masses between 16 and 30
kDa. Using staining with two antibodies specific for differ-
ent PrP-sites, WB can even discriminate between scrapie
and experimental BSE infection in sheep brain due to dif-
ferential cleavage of PrPres by proteinase K (PK) [21,22].
In this study we investigated the applicability of PrPres WB
to retropharyngeal lymph nodes (RLN) since these organs
are easily accessible at slaughter and are one of the best
targets for diagnosis in the lymphoid system [13,17,23].
This was performed on three groups of sheep: firstly,
sheep from an early and late scrapie pathogenesis study
with mainly genotype VRQ/VRQ (only codons 136, 154
and 171 of PrP are indicated in single letter amino acid
code); secondly, ARQ/ARQ sheep with orally induced
BSE; and thirdly, sheep diagnosed during active and pas-
sive surveillance in the years 2002–2003. The latter group
represented six different PrP genotypes.
Results
Antibody choice and fine epitope specificity
In lymphoid tissues PrPres  concentrations have been
reported to be 20 times lower than in brain [24]. There-
fore, monoclonal antibodies (mAbs) with superior affin-
ity for ovine PrP in Western blot (WB) were sought. Ten
mAbs (SAF84, SAF70, P4, L42, 8G8, 34C9 6H4, 94B4,
12B2 and 9A2) with specificity for ovine PrP were com-
pared on WB strips by varying two parameters: mAb con-
centration and amounts of ovine scrapie brain digest (see
Methods section). As a result, antibodies 12B2, P4, 9A2,
and L42 were selected as the most reactive. The epitope
specificities of these four mAbs were determined by Pep-
scan analysis on solid phase synthetic ovine PrP peptides
(Figure 1). Synthetic peptides carrying these epitope
sequences were also used in solution to investigate by
ELISA their capacity to block binding to recombinant
ovine PrP. Indeed, as can be expected for antibodies that
are elicited with peptides, all four of these could interfere
effectively with antibody binding to PrP, confirming the
significance of the mapped specificities (Table 1).BMC Veterinary Research 2006, 2:19 http://www.biomedcentral.com/1746-6148/2/19
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Tissue treatment and choice of retro-pharyngeal lymph 
node
A practical means of homogenisation was chosen for ton-
sillar and medial retropharyngeal lymph node (RLN) tis-
sue by using disposible homogenisers available for mass
screening purposes. Prypcon homogenisers were preferred
since these consistently yielded satisfactory suspensions
while other probes caused formation of gel in the
homogenate.
Homogenates of tonsils and RLN from scrapie-infected
sheep were examined after enzymatic hydrolysis with pro-
teinase K (PK) and/or deglycosylation with PNGaseF (Fig-
ure 2). Digestion with PK resulted in the typical triplet of
diglycosylated, monoglycosylated and aglycosyl PrPres.
Subsequent removal of carbohydrate moieties by
PNGaseF led further to a prominent single deglycosylated
PrPres band. There were no major differences in PrP immu-
nostaining between tonsils and RLNs.
In further studies, RLN tissue was used as the preferred tis-
sue for evaluating lymphoid tissues, since in contrast to
tonsillar tissue, it lead to reproducible scrapie diagnosis
and organ size was large enough for repetitive analysis.
This better reproducibility is likely due to a more homo-
geneous distribution of PrPSc in RLN compared to tonsils.
Also, at slaughter, RLNs are more easily accessible in the
decapitated head than are tonsillar tissues.
Diagnosis of scrapie in sheep during the incubation phase
We wished to know first, whether WB could detect scrapie
in the preclinical phase. As reported previously, VRQ/VRQ
sheep from our scrapie-infected flock are IHC positive in
tonsils and RLN at two months of age [25,26]. RLN sam-
ples of 18 such sheep, as well as of 6 scrapie negative
sheep (4 VRQ/ARR and 2 ARR/ARR genotypes), were
examined by WB. From the age of three months, WB
yielded results identical to IHC (Table 2). In 2-month old
cases, WB was negative, whereas IHC could detect PrP
only in fewer than 25% of the follicles. From the age of
four months onwards, all VRQ/VRQ sheep were positive
in both IHC and WB. A 20-fold concentration step allow-
ing application of 20 mg tissue equivalents (TE) per lane
instead of 1 mg yielded a proportionally stronger signal in
the positive cases, but did not change the diagnostic out-
come (data not shown). The RLN samples from the 6
scrapie negative sheep remained WB negative.
Table 1: Epitope specificities of 4 mouse monoclonal antibodies used.
antibody elicited with sequence epitope core by Pepscan analysis† blocking ELISA‡
89–107 145–177
12B2 bovine PrP97-115§ 93WGQGG97 yes no
P4 ovine PrP89-104 93WGQGGSH99 yes no
9A2 bovine PrP97-115§ 102WNK104 yes no
L42 ovine PrP145-163 148YEDRYY153 no yes
†Mapping of antigenic sites in the ovine PrP sequence for 4 monoclonal antibodies by Pepscan analysis.
Shown are shared sequences (core of epitope) of overlapping 15-mer antigenic peptides for antibodies 12B2, P4, 9A2 and L42 from Figure 1. 
Numbers refer to ovine PrP sequence Genbank accession nr. AJ567985.
‡Blocking was 100% in all positive cases and 0% in all negative cases with peptide concentrations of ≥ 0.5 μg/ml and antibody concentrations ≤ 0.5 
μg/ml.
§Corresponds to ovine PrP sequence 89–107. Antibodies produced by [60]
Mapping of antigenic sites in the ovine PrP sequence for 4  monoclonal antibodies by Pepscan analysis Figure 1
Mapping of antigenic sites in the ovine PrP sequence 
for 4 monoclonal antibodies by Pepscan analysis. For 
each antibody indicated, results of analyses are presented for 
peptides 76–175. Antigenic peptides for the respective anti-
bodies 12B2, P4, 9A2, and L42 are: 83–93, 85–93, 90–102 
and 139–148. See Table 1 for deduced core of the epitopes.BMC Veterinary Research 2006, 2:19 http://www.biomedcentral.com/1746-6148/2/19
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When tested by WB, brain tissue from the VRQ/VRQ ani-
mals scored positive from 17 mo of age onwards, which
was some 7 mo later than by IHC. Compared to uncon-
centrated samples, application of 20 mg TE after a preced-
ing concentration did not lead to earlier detection of
PrPres. By WB, scrapie diagnosis using RLN from these
sheep was already possible at 3 mo of age, while a positive
diagnosis with brain was obtained only from 17 mo of
age, thus illustrating that WB on lymphoid tissue can lead
to a scrapie diagnosis at a very early stage of infection.
Diagnosis in animals in preclinical and clinical phase of 
experimental BSE
RLNs from sheep with experimental BSE, in a previous
[27] and ongoing study, were examined by WB. All 11
infected animals of this study were positive by WB, but
only after concentration to 10–20 mg TE/lane. (Table 3; 4
clinical, 7 preclinical cases). If no concentration treatment
was included and mAb L42, the best antibody for BSE, was
used, 6 out of 7 animals in the preclinical stage, and 2 out
4 in the clinical stage, could be diagnosed. Thus, in the
case of BSE, concentration improves the diagnostic sensi-
tivity. Surprisingly while all animals were positive by WB,
one with the shortest duration of infection (6 mpi) was
negative by IHC.
Antibodies showed different affinities for PrPres in BSE-
and scrapie-infected sheep (Figure 3). PrP-core specific
antibodies L42 and 9A2 recognized PrPres in BSE samples,
with the former being the best antibody. PK-cleavage site
specific antibodies 12B2 (and P4) hardly bound to PrPres
from BSEinfected samples. Remarkably, 9A2 bound less
strongly to PrPres in BSE samples than L42, contrary to
findings with scrapie-infected sheep. It seems, thus, that
the 9A2 epitope in BSE samples could be more prone to
PK cleavage than that in scrapie. Variable cleavage of PrPSc
is a recognized phenomenon, but the extent or pattern of
these cleavages could well depend on agent-specific PrP-
conformational properties, which in situ might result in
differences in antibody binding between potentially dif-
ferent TSE strains [22,27-31]. These results also emphasize
that for discrimination between scrapie and BSE in dual
antibody staining, the use of core antibody L42 is prefera-
ble to 9A2, especially in weakly positive samples.
Diagnosis of scrapie in field cases from surveillance and 
with mostly unknown ages
RLNs from sheep with various PrP genotypes and from
different sources, were examined by WB and IHC. In gen-
eral, again, there was a good correlation between the two
methods, since divergent results occurred only for some
weak IHC-positive cases (Table 4; and for individual data
see Table in "additional file 1"). Thus, 51 out of 61 brain-
positive sheep were diagnosed to be scrapie positive with
RLN by both methods and two others were only positive
by IHC. Within the different genotypes, WB of RLN scored
5 out of 7 positive in the ARQ/ARQ group, (while IHC
scored one more, 6/7), and 1 out 9 (IHC 2/9) in the ARR/
VRQ group. For the other genotypes (VRQ/VRQ, ARQ/
VRQ, ARH/VRQ, ARQ/ARR), the two tests corresponded
fully with each other. In brain-negative sheep, 1 out 7
appeared positive with both WB and IHC. This one lym-
phoreticular system (LRS) positive case was an ARQ/VRQ
animal, 65 mo of age, derived from our own flock with
minimal scrapie-incidence. Further concentration up to
10 mgTE/lane yielded higher signals proportional to the
Western blotting of homogenates from scrapie positive ton- sil and retropharyngeal lymph node Figure 2
Western blotting of homogenates from scrapie posi-
tive tonsil and retropharyngeal lymph node. Tonsillar 
(lanes 1, 3) and medial retropharyngeal lymph node (lanes 2, 
4) material digested with proteinase K was analyzed by WB 
and developed with monoclonal antibody P4 (0.2 μg/ml). 
Enzymatic treatment with PNGaseF is indicated. Lanes 1–4: 
Applied amounts 450 μg TE/lane. Lane 5: molecular weight 
markers. Position of markers are in kDa. Other symbols: 
open arrowhead for top of gel, bold arrowhead for front of 
bromphenol blue, bracket for migration position of PrPres tri-
plet, small lines for the three individual PrPres polypeptides in 
the triplet as discussed in the Results section. Position of 
markers is in kDa. Band at 14 kDa represents lysozyme from 
SeeBlue Mark12 which is bound by anti-mouse alkaline phos-
phatase conjugate.BMC Veterinary Research 2006, 2:19 http://www.biomedcentral.com/1746-6148/2/19
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10× concentration factor, but the diagnostic result in this
set of samples was the same as found for the unconcen-
trated samples.
Molecular weight and glycoprofiles of PrPres bands
Apparent molecular weights (MWr) of the three PrPres
bands in WB of RLN digests were compared for a correla-
tion by type of infection (scrapie or BSE), stage of incuba-
tion or genotype. A BSE-specific difference in the MWr
existed and was especially distinct for the aglycosyl moi-
ety, which was about 1kDa larger in scrapie samples than
in BSE samples (Table 5). This appeared to be the case for
both antibodies 9A2 and L42. Antibody 12B2 (and P4,
not shown) only bound well to the scrapie-infected sam-
ples (Figure 3) indicating that, as in brain stem tissue [22],
a discrimination between scrapie and BSE by dual WB
staining is possible using lymphoid tissues, i.e. comparing
the immunostaining of a sample for PrP-core specific anti-
body (e.g. 9A2 or L42) and PrPres N-terminus specific anti-
bodies (12B2 or P4). However, no marked differences in
MWr  for the PrPres  bands (not shown) were observed
between preclinical and clinical stages of incubation or
between scrapie sheep with different genotypes.
Glycoprofiles found in individual RLN samples are pre-
sented on a triangular graph which allows visualisation of
the relative concentration of all three PrPres bands, i.e., the
di-, mono-, and aglycosyl moieties (Figure 4). The appar-
ent variations in glycoprofile were further analyzed for
correlation with TSE-type, TSE-incubation stage, and gen-
otype. Firstly, for the TSE-types, the diglycosyl fraction of
PrPres in scrapie samples of the surveillance group and pre-
clinical study were around 54% (range 45–65), while in
BSE-infected sheep in the preclinical and clinical phases,
respectively, it constituted 64% (range 58–68) and 74%
(range 69–82). These 3 values were significantly different
from each other (P < 0.001), and similarly, the aglycosyl
and monoglycosyl fractions were statistically different
Table 2: Sheep with preclinical scrapie*.
diagnosis
sheep nr genotype age (m) IHC WB
brain RLN† brain‡ RLN‡
PS-5 VRQ/VRQ (n = 18) 2 - 1+ - -
PS-6 2 - 1+ - -
PS-3 3 - 2+ - 2+
P S - 4 3 - ---
PS-1 4 - 4+ - 3+
PS-12 4 - 3+ - 2+
PS-7 5 - 4+ - 3+
PS-8 5 - 4+ - 1+
PS-10 5 - 4+ - 1+
PS-11 5 - 3+ - 2+
PS-18 10 1+§ 4+ - 2+
PS-17 13 1+ 4+ - 2+
PS-15 14 2+ 4+ - 2+
PS-16 14 2+ 4+ - 3+
P S - 1 4 1 7 3 + 4 +1 +2 +
P S - 1 3 2 1 3 + 4 +3 +2 +
PS-23 26¶ 3+ 4+ 3+ 2+
PS-24 26¶ 3+ 4+ 3+ 1+
PS-21 ARR/VRQ (n = 4) 17 - - - -
P S - 2 2 1 7- ---
P S - 1 9 2 4- ---
P S - 2 0 2 4- ---
PS-2 ARR/ARR (n = 2) 3 - - - -
P S - 9 6 - ---
* open flock of Texel cross breed with natural scrapie; – means no PrP or PrPres detected.
† number of plus signs indicate % of follicles PrP-positive 1+ = <25%, 2+ = 25-50%, 3+ = 50–75%, 4+ = 75–100%.
‡ 1+ = weak signal for all three PrPres bands; 2+ = PrPres bands well visible; 3+ = PrPres bands so dark that diglycosyl and monoglycosyl are merging 
together at 6 min film exposure. Results obtained with either of the antibodies 12B2, P4 or 9A2 after SDS-PAGE of non-concentrated samples, or 
with 12B2 and concentrated samples.
§ In a previous study, another 10 m old RLN positive animal was found negative in the brain by IHC [25].
¶ Clinical signs.BMC Veterinary Research 2006, 2:19 http://www.biomedcentral.com/1746-6148/2/19
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between 4 groups of cases – preclinical scrapie, surveil-
lance, preclinical BSE and clinical BSE (P < 0.001). Sec-
ondly, linear regression analyses on both BSE and
preclinical scrapie samples yielded slightly decreasing
trends with stage of incubation for the aglycosyl and
monoglycosyl PrPres  fractions, and a concomittant
increase in the diglycosyl fraction. The slopes for these
stage-dependent trends, however, were unlikely to deviate
significantly from zero for either the BSE cases or the cases
in the preclinical scrapie study (P > 0.05). This trend was
not due to a technical artifact since no correlation between
glycoprofile and concentration of PrPres existed. No signif-
icant differences were found for the relative concentration
of each of the glycoforms of PrPres between genotypes in
the scrapie surveillance group (P > 0.05).
Discussion
This study shows that medial retropharyngeal lymph
nodes (RLN) are a suitable target for monitoring scrapie
and BSE in sheep, including young lambs. The animals
examined were sheep with natural scrapie or experimental
BSE in clinical and preclinical stages of the disease, and
sheep from an active surveillance program with IHC pos-
itive brain but unknown age or clinical status. The diag-
nostic technique used was Western blotting with several
high affinity PrP-specific antibodies. The best results were
obtained with antibodies that bind to both scrapie and
BSE PrPres (9A2, L42). Sheep of the VRQ/VRQ genotype
scored positive from the age of three months, at a stage
when the brain was still negative. To intercept as many
infected sheep as possible, both brain tissue and lymph
nodes have to be examined, since VRQ animals with allele
combinations other than VRQ/ARR, and many of the
infected ARQ/ARQ sheep, will be positive in RLN much
earlier than in brain, whereas a fraction of the ARQ/ARQ,
Typical PrPresprofiles in scrapie and BSE infected retropha- ryngeal lymph nodes using different antibodies Figure 3
Typical PrPresprofiles in scrapie and BSE infected ret-
ropharyngeal lymph nodes using different antibodies. 
Type of specimen applied: lanes 1 and 7 molecular weight 
markers in kDa; lane 2 brain stem homogenate from ARQ/
VRQ sheep with scrapie; lane 3, RLN from VRQ/VRQ 
scrapie sheep at age 26 m; lane 4, RLN from BSE-infected 
ARQ/ARQ sheep in preclinical stage of disease; lane 5, RLN 
from ARQ/ARQ sheep with subclinical (brain positive, no 
clinical signs) stage of scrapie; lane 6, RLN from BSE-infected 
ARQ/ARQ sheep in clinical stage of disease. Amounts of tis-
sue applied: lane 2, 200 μg TE, lanes 3–6, 10 mg TE. Antibody 
concentrations used: L42 and 12B2, 0.2 μg/ml; 9A2, 2 μg/ml.
Table 3: Post mortem diagnosis in RLN of sheep with experimental BSE in preclinical and clinical status*.
sheep nr. m.p.i. at euthanasia IHC† WB‡
2117 6 -¶ 2+
6869 9 + 1+
2114 12 + 2+
3903 13 + 2+
3907 15 + 2+
3905 17 + 2+
2112 19 + 2+
2140 21§ +2 +
2115 21§ +2 +
2138 23§ +2 +
2116 24§ +2 +
* Oral inoculations occurred between 4–6 mo of age. Each animal received 5 g of bovine BSEinfected brain by oral route [27].
† Positive in tonsil and RLN.
‡ 1+, weak signal for all three PrPres bands. 2+ PrPres bands clearly visible. Results after concentration obtained with either of the antibodies 9A2 or 
L42; antibody 12B2 scored negative in all samples.
§Clinical signs.
¶ Weakly positive in tonsil and ileal Peyer's patches.BMC Veterinary Research 2006, 2:19 http://www.biomedcentral.com/1746-6148/2/19
Page 7 of 14
(page number not for citation purposes)
and most ARR/VRQ sheep, may only be positive in the
brain. Inclusion in the procedure of a simple concentra-
tion step with high PrPres recovery improved the sensitivity
of detection of BSE infected animals.
There is still too little knowledge available about the time
of appearance of disease-associated PrP in the LRS of
sheep with scrapie. This stage will vary with infection pres-
sure, age, strain and genotype. For example, the earliest
stage in this study, as in some other studies [16,17], was
2–3 months of age in the most susceptible sheep (geno-
type VRQ/VRQ), in heavily infected flocks. LRS positivity
at preclinical stages of natural scrapie in sheep with other
genotypes, such as ARQ/VRQ and ARH/VRQ was noticed
at ages varying between 10–24 months, while clinical dis-
ease developed later, at more than twice that age [32]. Pre-
clinical accumulation of PrP in LRS tissues has been found
in naturally infected Suffolk sheep with ARQ/ARQ geno-
type between 8–20 months of age [33,34]. Detection of
BSE PrPres by WB in RLN of ARQ/ARQ sheep was possible
at 6 months post-infection (pmi), the earliest stage inves-
tigated, and in all other animals at later stages. The diag-
Table 5: Molecular weight estimations of PrPres form in retropharyngeal lymph nodes and brain stem*.
scrapie
RLN brain stem
antibody L42 9A2 12B2† 9A2
PrPresform
diglycosyl 28.8 ± 0.7 28.9 ± 1.9 29.2 ± 0.8 28.6 ± 1.4
monoglycosyl 22.4 ± 0.5 22.9 ± 1.0 22.8 ± 0.2 22.7 ± 0.5
aglycosyl 18.8 ± 0.4 19.0 ± 0.8 18.9 ± 0.1 18.6 ± 0.5
BSE
RLN brain stem
antibody L42 9A2 12B2† 9A2
PrPresform
diglycosyl 28.5 ± 1.3 28.9 ± 2.0 N.R. 28.3
monoglycosyl 21.9 ± 1.1 22.2 ± 2.1 N.R. 22.5
aglycosyl 17.8 ± 0.8 18.0 ± 1.7 N.R. 18.0
* Values are in kDa and presented as average ± SD, from 3 different experiments with at least 4 different individual animals per experiment, except 
for mAbs 12B2 (n = 2) and 9A2 on BSE infected brain stem, n = 1.
† Antibody 12B2 yielded the same MWr as P4 in scrapie samples; N.R. = no reactivity.
Table 4: Scrapie diagnosis in medial retropharyngeal lymph nodes from animals mostly with unknown age at death*.
scrapie positive in CNS scrapie negative in CNS
WB IHC WB IHC
all genotypes 51/61 53/61 1/7 1/7
per genotype
ARQ/ARQ 5/7 6/7 0/1 0/1
ARQ/ARR none none 0/2 0/2
VRQ/VRQ 6/6 6/6 none none
ARQ/VRQ 32/32 32/32 1†/2 1†/2
ARH/VRQ 7/7 7/7 none none
ARR/VRQ‡ 1/9 2/9 0/2 0/2
* Sources of animals were own flocks, clinical suspects, and slaughtered or fallen stock animals aging >18 m collected under EU surveillance 
program for small ruminants (see Methods section and for individual data Table in "additional file 1"). Figures indicate the number of positives/total 
number of animals analyzed. The analyses on central nervous system (CNS) were performed by Prionics Check and IHC, and concerned obex 
tissue analysis.
† Animal aging 65 m, found dead from minimal scrapieincidence pressure flock.
‡ There were two samples (RLN65 and RLN67) which in three WB tests yielded once a weakly positive result, and twice (including after a 
concentration treatment) a negative result. In IHC, RLN65 was weakly positive, RLN 67 negative.BMC Veterinary Research 2006, 2:19 http://www.biomedcentral.com/1746-6148/2/19
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nostic score by WB in our BSE-study on RLN was nearly
similar as to that obtained by IHC, except for the animal
with shortest incubation (6 mpi, Table 3) which by WB
was positive but by IHC was negative. However, in this
same animal tonsil and ileal Peyer's patches were weakly
positive. Discrepancies in the detection of disease-associ-
ated PrP in RLN between IHC and WB might be due to
sensitivity of tests or a difference in level of detectable dis-
ease-associated PrP between left and right side in the head
at early stage of appearance.
Signs of preclinical infection have been reported in vis-
ceral LRS of ARQ/ARQ Suffolk sheep from 4 months post-
infection [35]. It must be borne in mind that the dose of
5 g brain tissue for oral BSEinfection is unusually high and
that only ARQ/ARQ animals have been investigated. It is
unlikely that such levels have been reached in the field
with BSE- contaminated with BSE. However, it is likely,
based on IHC studies, that the phenotype of BSE PrPSc in
sheep is not altered by either PrP-genotype or route of
challenge, while on the other hand, it might be assumed
that the accumulation of PrPSc  varies depending on
incoming strain and host genotype [36,37].
Scrapie in sheep is not always accompanied by detectable
lymphoid involvement [13,15,16,25,26,32,38,39]. For
instance, ARR/VRQ sheep are usually LRS negative. Our
data obtained from RLN agree with these observations,
with 84% (52/62) of RLN samples in scrapie positive
sheep from surveillance scoring positive by WB. Others
report a rate between 88–93% for LRS diagnosis in brain
positive animals with only XXQ/XXQ genotypes (X's indi-
cate any known variation at respectively codon 136 and
154) [38,40]. In general, scrapie sheep of all PrP geno-
types except ARR/VRQ tend to become positive in LRS,
while the ARR/VRQs become solely brain positive, and
then in only a limited number of animals, at high ages
[13,16,17,32-34,40-44]. There are, however, exceptions to
the involvement of the LRS with scrapie, as others have
reported, and as was also observed in this study
[23,40,43,45,46]. One out of our 7 ARQ/ARQ sheep with
a scrapie diagnosis in the brain was negative in the lym-
phoid system. Further, we found all brain positive VRQ/
VRQ, VRQ/ARH and ARQ/VRQ sheep to be RLN positive,
but Jeffrey [45] reported two (out of 24) ARQ/VRQ sheep
to be negative outside the central nervous system. The first
ARR/VRQ sheep with involvement of the lymphoid tissue
was reported by Ersdal [46] who described an 86 day old
lamb with IHC positive Peyer's patches in the ileum. We
found two sheep of this genotype with positive lymphoid
tissues. Recently, 3 cases of susceptible XXQ/XXQ geno-
type were reported with positive diagnosis in brain, while
negative in all gut-associated lymphoid tissues studied,
and which scored positive in the spleen [40]. As well, in
infections with the recently described Nor98 strain of
scrapie, no PrPres deposits have been detected so far in
lymphoid tissues. The Nor98 condition has only been
diagnosed by examination of the brain, and then, prima-
rily the cerebellum regions [47]. Likewise, no deposits of
PrPSc have been detected in LRS tissues of sheep intracere-
brally infected with CH1641, an experimental sheep
scrapie strain that exhibits similar migrational properties
for PrPres as BSE in sheep [21,48] (our own observations).
Other techniques, such as ELISA and IHC with brain or
LRS, might assist in further classification of dubious cases
[48,49]. In summary, while the involvement of peripheral
tissues in all clinical or preclinical classical scrapie is not
absolute, nevertheless, it occurs with sufficient regularity
to be of use in surveillance systems and potentially pro-
vides earlier pre-clinical diagnosis than would be achieved
by analysis of CNS tissues.
Different methods for PrPres concentration from homoge-
nates were used, depending on the tissue source: centrifu-
Glycoprofile of PrPres in RLN samples analyzed in scrapie and  BSE infected sheep Figure 4
Glycoprofile of PrPres in RLN samples analyzed in 
scrapie and BSE infected sheep. Triangular presentation 
of the proportion of each of three glycoprofile components 
per individual RLN sample. Symbols correlate with group of 
sheep: ● – field cases,  – scrapie cases in preclinical study 
(excluding 2 clinical cases), ▲ – sheep with experimental BSE, 
 – sheep in preclinical stage of experimental BSE. The aver-
age and SDs per group is indicated by respectively the larger 
size symbols and bars. The small triangle diagram indicates in 
which direction from the axes each point should be read.BMC Veterinary Research 2006, 2:19 http://www.biomedcentral.com/1746-6148/2/19
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gation for RLN without additives, and centrifugation after
addition of alcohols, for brain tissue. By allowing 20 mg
tissue equivalents to be tested, both methods lead to
increased sensitivity of detection of PrPres by WB com-
pared to no centrifugation. For RLN, it improved BSE
detection. However, four scrapie samples, that were
weakly positive by IHC, were not detected even after con-
centration: 2 preclinical RLN samples from VRQ/VRQ
sheep with scrapie at two months of age, and 2 RLN sam-
ples from routine diagnosis – 1 ARQ/ARQ and 1 ARR/
VRQ sheep. IHC of these few non-corresponding samples
appeared to be only weakly positive, indicating that, with
WB, it is possible, in principle, to detect most cases iden-
tified by IHC. In brain samples from animals between 10–
17 months of age (Table 2), WB might have missed posi-
tive diagnosis in 4 preclinical cases, since these analyses
possibly obex parts lacking dorsal motor nucleus of the
nervus vagus where the first positivity can be found [25].
In our hands the PrPSc precipitation technique described
by Wadsworth [24], which is based on the presence of
phophotungstic acid, gave unsatisfactory recoveries (≤
60%) after PK digestion. Recoveries were much better if
precipitation preceded PK digestion, but this approach
changed the mobility of the PrPres bands, making it diffi-
cult to rely on molecular weight determination to distin-
guish between strains.
When analysed by WB, glycoprofiles and apparent molec-
ular weights of PrPres in RLN digests were similar to those
reported for brain tissue of scrapie or BSE infected sheep
[22]. This means firstly, that, using RLN, both TSEs can be
detected in a single screening with the PrP-core specific
antibodies L42 or 9A2. Secondly, differentiation of BSE
and scrapie can be done subsequently, in a dual antibody
test using two blots, one with a PrP-core specific antibody,
such as L42 or 9A2, and the other with a PrPres N-terminus
specific antibody, such as P4 or 12B2. All these antibodies
have high affinity for ovine PrP. Glycoprofile analyses can
further support the differential diagnosis of scrapie and
BSE, where the relative amount of the diglycosyl moiety of
PrPres is lower in scrapie than BSE. However, glycoprofil-
ing remains an inconclusive tool in discriminating scrapie
from BSE cases since there is overlap in glycoprofile
between the scrapie and BSE cases (Figure 4). In other
studies glycoprofile analyses in sheep have yielded too
divergent results in scrapie cases to allow a discriminatory
diagnosis between scrapie and BSE [18,20,50,51]. Never-
theless, the relatively high concentration of the diglycosyl
PrPres fraction in BSE-infected animal species, including
humans with a variant form of Creutzfeldt-Jakob disease,
remains noteworthy [21,52-54]. A new factor in glyco-
form analyses of PrPres is the possible dependence on stage
of incubation. Though this was not statistically signifi-
cant, it was striking that in both our sheep TSE incubation
studies, experimental BSE in ARQ/ARQ sheep and natural
scrapie in VRQ/VRQ animals, a correlation was found,
revealing an age dependent increase in the diglycosyl moi-
ety of PrPres with a concomittant decrease in the a- and
monoglycosyl fractions. This association was not due to a
technical artifact since no correlation between glycopro-
file and concentration of PrPres. These time-related varia-
tions in protein glycosylation could be due to disease
status, but normal age dependent variations in posttrans-
lational processes during protein synthesis should also be
considered [55]. Finally, these glycoprofile variations fur-
ther indicate that, as a tool for discriminating scrapie from
BSE, glycoprofiling in sheep is a rather unreliable param-
eter when the age of the animal and the strain properties
of the isolate are not known. Likewise, in brain, further
studies are needed to establish a time-dependent relation
of PrPres-glycosylation.
This study was performed on samples collected during the
years 2002–2003 and appears to be a rather representative
cross-section of the Dutch sheep population, with respect
to the presence of the different genotypes (compare for
the years 1999–2001 in [22]). It remains to be seen how
consistently the RLNs score in different age groups, geno-
types and preclinical stages. Nevertheless, the efficacy of
detecting scrapie and BSE infection in current monitoring
programs can be highly improved for animals in a stage
where the TSE agent has not yet invaded the central nerv-
ous system, i.e., at ages younger than 18 months. At older
ages, both brain and RLN testing is needed to optimally
assure absence of TSE. It is expected that lymphoid testing
also enhance surveillance efficiency in goats, where the
lymphoid system usually is involved [11,14,56] (Van Keu-
len personal communication).
Conclusion
This study demonstrates that Western blotting can be used
for routine screening of classical scrapie and BSE in retro-
pharyngeal lymph nodes of sheep at slaughter with a sen-
sitivity nearly the same as immunohistochemistry. A con-
centration step for PrPres is required. The difference in
polypeptide length of PrPres between BSE and scrapie can
be unequivocally confirmed by dual antibody staining
using two classes of antibodies: one which binds to the N-
terminus of PrPres in scrapie only, and one which binds to
the core of PrPres in both BSE and scrapie.
Methods
Sheep and tissues
Sheep used were from our own flock, from slaughter or
fallen stock. In total, 103 sheep were used in this study.
For preclinical and clinical scrapie, 24 animals with
known ages were used (Table 2). These animals have been
described previously in immunohistochemical (IHC)
pathogenesis studies [25,26] and were bred within ourBMC Veterinary Research 2006, 2:19 http://www.biomedcentral.com/1746-6148/2/19
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own Texelcross flock with natural scrapie. The animals
were euthanized and sampled at ages from 2-26 months.
18 sheep were of VRQ/VRQ genotype. Potentially nega-
tive controls from the same flock comprised 4 ARR/VRQ
(ages 17, 17, 24, and 24 months) and 2 ARR/ARR animals
(ages 3 and 6 months).
For preclinical and clinical BSE, 11 sheep of ARQ/ARQ
genotype were orally fed with bovine BSE brain as previ-
ously described [27]. Four of these animals were kept until
clinical signs of disease appeared, the others were eutha-
nized between 6 – 19 months post-infection. These ani-
mals were positive by IHC for PrPSc in their tonsils at
biopsy or at autopsy (Table 3).
The remaining 68 sheep were from different surveillance
sources, most of them of unknown ages (see for individual
data Table in "additional file 1"). Within this group, 12
animals with and without clinical suspicion of scrapie
were obtained from either our own flock with natural
scrapie (n = 5), our own flock maintained with minimal
scrapie-incidence (n = 3), private farms with clinically sus-
pect cases (n = 3), or a private farm with known history of
scrapie (n = 1, normal animal). Of the remaining sheep,
most were diagnosed through the active surveillance pro-
gram for slaughter (n = 50) and fallen stock (n = 6). The
heads of the animals in the monitoring program had been
kept at 4°C for up to three days. Seven of the 68 animals
were TSE negative in the brain by rapid testing and IHC,
with one of these 7 being TSE positive in tonsil and RLN
by IHC.
Brain and lymphoid tissues were collected for IHC and
biochemical assays. From brain, one parasagitally cut lon-
gitudinal half was fixed in formaldehyde and embedded
for pathological and immunohistochemical analysis [25];
the other smaller part was stored at -20°C. Lymphoid
organs from one side of the animal were sampled for IHC,
and from the other side were stored at -20°C for biochem-
ical assays.
Scrapie diagnosis
The Prionics-Check Western blot method for active mon-
itoring of BSE in cattle was used [57] for routine scrapie
diagnosis on brain stem at the obex region. This method
uses digestion with proteinaseK at 50°C and PrP-specific
monoclonal antibody 6H4 for detection. Scrapie was fur-
ther confirmed by immunohistochemical (IHC) analysis
on brain and lymphoid tissues according to established
procedures with the various antibodies described and
characterized previously [13,27,58].
Genotyping
Blood from sheep were used for PrP genotyping for PrP
codons 136, 154, and 171 using two genotyping tech-
niques, i.e., TaqMan analysis and, for confirmation of Arg,
Gln or His at codon 171, Pyrosequencing [22,44]. To
exclude mistakes by exchange of samples, genotype was
also checked in homogenates of RLN and brain stem.
Antibodies and fine epitope mapping by Pepscan analysis, 
peptide synthesis and blocking ELISA
Antibodies used for WB were from different sources. The
following murine PrP-specific monoclonal antibodies
(mAbs) were purchased: P4, L42 (R-Biopharm, Almere,
The Netherlands), 8G8, SAF70, SAF84 (SPI-BIO, Mon-
tigny le Bretonneux, France), 34C9 and 6H4 (Prionics AG,
Zurich, Switzerland). These mAbs were prepared as
described [59-62]. MAb 94B4 was previously described
[22] and mAbs 12B2 and 9A2 were newly prepared using
PrP-knockout mice [63] immunized with peptide
GGGGWGQGGTHGQWNKPSK (bovine PrP 97–115),
conjugated through a cysteine at its Cterminus to Keyhole
limpet hemocyanine using previously described proce-
dures [64]. Immunisations were carried out in the pres-
ence of incomplete Freund's adjuvant (first injection) or
adjuvant CoVaccine HT (CoVaccine, Utrecht, The Nether-
lands) in 4 administrations evenly distributed over a
period of 63 days. Animals were bled and spleens used for
hybridisation to Sp2/0 myeloma cells according to stand-
ard procedures. Screening for PrP-specific antibodies in
sera and culture supernates was performed by indirect ELI-
SAs using the peptide, recombinant ovine PrP (kind gift of
T. Sklaviadis, Aristotle University, Thessaloniki, Greece)
and bovine PrP (Prionics AG) as coated antigens at 0.2,
0.2, and 0.1μg/ml, respectively. The fine epitope specifici-
ties of 12B2, 9A2 and L42 were determined by Pepscan
analyses with overlapping 15-mer solid phase peptides
using the ovine PrP sequence as sequence basis as previ-
ously described [22,65], and further confirmed in ELISA
by blocking antibody binding to coated recombinant
ovine PrP, using synthetic peptides. Blocking ELISA was
performed as follows: polystyrene microtiter plates were
coated overnight at 4°C with recombinant ovine PrP at
0.1 μg/ml in 6 M guanidinium-HCl in PBS (138 mMNaCl,
2.7 mM KCl, 8 mM Na2HPO4, 2.8 mM KH2PO4, pH7.2).
Plates were washed with 0.05% Tween-20 in water. In sep-
arate microtiter plates antibody plus peptide was preincu-
bated overnight in 1% (w/v) Tween80, 4% (v/v) horse
serum, 0.35 M NaCl in PBS (ELISA medium). The anti-
body-peptide mixture was transferred to the plate coated
with PrP. After 1 h at ambient temperature, plates were
washed as before and further developed by addition of
horseradish peroxidase-rabbit anti-mouse Ig conjugate
(DAKO, Denmark) diluted 1/1000 in ELISA medium.
Bound antibody was spectrophotometrically measured at
450 nm after addition of 3,3',5, 5'tetramethylbenzidine
for 20 min and stop of the reaction with sulphuric acid.
Synthetic peptides used for blocking in solution were:BMC Veterinary Research 2006, 2:19 http://www.biomedcentral.com/1746-6148/2/19
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ovine PrP145-177 and PrP89-107 (Genbank accession
number AJ567985).
Tissue treatment
Tonsils and medial retropharyngeal lymph node tissue
were macroscopically freed from surrounding fat and con-
nective tissue. 10% homogenates were prepared by
homogenisation in lysis buffer consisting of 0.5%Triton
X-100, 0.5%Nadeoxycholate, in PBS. Homogenisation
was performed for 1 min in either 50 ml Falcon tubes and
OmniTP equipment with disposable probes (Omni Inter-
national Inc., Warrenton, VA, USA) at 30,000 rpm or for
45 s at 23,000rpm in Prypcon Lymph Node 80300/B vials
with MediFASTH homogeniser (Consul AR SA, Ville-
neuve, Switzerland). For storage purposes, homogenates
were clarified in 1.5 ml Eppendorf vials by centrifugation
at 10,000 × g for 10 min at ambient temperature. After
addition of 10 μl of 550 μg/ml proteinaseK (PK, 30 U/mg,
124568, Merck, Darmstadt, Germany) in PBS to 100 μl of
homogenate, digestion was performed for 40 min at
50°C. The reaction was subsequently by addition of 10μl
of a Pefabloc solution (3 mg/ml Pefabloc SC in PBS;
Roche, Almere, The Netherlands), 100 μl 2× sample buffer
(20% [w/v] sucrose, 0.282M Tris-Base, 0.212M Tris-HCl,
4% [w/v] Nadodecylsulphate, 1.0 mM EDTA, 0.038% [w/
v] bromephenol blue, 4% [v/v] β-mercaptoethanol), and
heating for 5 min at 95°C. On some occasions, concentra-
tion of PrPres in RLN was first carried out by centrifugation
of 100 μl digest in 1.5 ml vials at 14,000 rpm, 21,000 xg
for 1 h in an Eppendorf 5417R centrifuge at 4°C as
recently described [66]; pellets were dissolved by subse-
quent addition of 10 μl 0.1 % N-lauroylsarkosine in PBS
and 10 μl of 2× sample buffer. Samples were heated for 5
min at 95°C.
Brain stem tissue from scrapie sheep was homogenized
and digested either according to the protocol of a routine
test (PrionicsCheck) or treated as above for RLN. To
enhance sensitivity, PrPres was concentrated as follows:
after digestion with PK and addition of Pefabloc, the
digest was mixed with 100 μl of a mixture of propan-2-ol/
n-butan-1-ol (1/1, v/v) and centrifuged for 5 min at
21,000 xg in a microcentrifuge at room temperature
(Eppendorf). The pellet was finally dissolved in 1× sample
buffer (2 × sample buffer diluted with an equal volume of
water). The recovery of PrPres in this procedure for concen-
tration was consistently >90% when comparing equal tis-
sue equivalents of unconcentrated and concentrated
material, allowing the application of 20 mg tissue equiva-
lents (TE) per lane, instead of 1 mg TE in unconcentrated
state. This concentration method employed the protein
precipitating properties of alcohols while removing
SDSPAGE-disturbing components from brain tissue.
Deglycosylation treatment with PNGaseF
Removal of asparagine-linked oligosaccharides after PK
digestion was performed as follows, After blocking the PK
reaction with Pefabloc, 10 μl of denaturation buffer (5%
sodium dodecyl sulfate [SDS], 10% β-mercaptoethanol in
20 mM Tris-HCl, 150 mM NaCl, 2 mM EDTA [pH 7.5])
was added to the sample. This was heated for 10 min at
95°C. After cooling, 10 U of PNGaseF (New England
Biolabs, Beverley, USA) was added and incubated over-
night at 37°C. To stop the reaction, 100 μl of 2× sample
buffer was added and the mixture heated for 5 min at
95°C.
SDS-PAGE, Western blotting, and immunochemical 
development
SDS-PAGE was performed with 10-well precast 1 mm
12% BisTris NuPAGE gels (NuPAGE gel electrophoresis
system with MOPS buffer; Invitrogen, Breda, The Nether-
lands). Molecular weight markers used were MagicMark
and SeeBlue Mark12 (Invitrogen). Sample volumes
applied varied between 10 to 20 μl per lane, or 0.5 – 10
mg tissue equivalents (TE)/lane. Electrotransfer onto pol-
yvinylidene difluoride membranes (PVDF, Immobilon-P;
Millipore, Bedford, Mass.) and immunostaining were per-
formed according to established procedures [, ]. After elec-
trotransfer, blots were blocked for 30 min with 5%skim
milk protein in antibody incubation solution (25 mM
Tris-HCl, 0.15 M NaCl, 2.7 mM KCl, 0.05% Tween20 at
pH7.4). Primary antibodies were used at concentrations
between 0.2–2 μg IgG/ml in antibody incubation solu-
tion. Secondary antibody used was rabbit anti-mouse
immunoglobulinG conjugated to alkaline phosphatase
(Dako, Glostrup, Denmark). Signal was developed with
CDPStar by following the supplier's instructions (Tropix,
Bedford, Mass.) and were recorded on photographic film,
usually with exposure times between 1–45 min (Hyper-
film ECL; Amersham, Buckinghamshire, United King-
dom). Molecular weights were determined according to a
method described []. To estimate glycoprofiles of PrPres i.e.
the relative proportions of di-, mono-, and aglycosyl frac-
tion, films were recorded with an Agfa Duoscan T200XL
scanner and further processed with GelPro software
(MediaCybernetics, Silver Spring, MD) from which calcu-
lation of mutual densities of the three protein bands was
possible. In experiments to compare the relative affinity
for ovine PrPres, antibodies were applied in concentration
series on PVDFstrips from blots transferred from single
well gels run with ovine scrapie infected brain stem
homogenates varying between 1.25–20 mg tissue equiva-
lents (TE).
Statistical analyses
One-way analyses of variance (ANOVA) were carried out
to establish whether variations between groups of data, in
casu  glycoform fractions of PrPres, were greater thanBMC Veterinary Research 2006, 2:19 http://www.biomedcentral.com/1746-6148/2/19
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expected; if so, subsequent differences between pairs of
groups were considered significant if the probability of a
difference was <0.05 in multiple-comparisons tests
according to the Student-Newman-Keuls test. Linear
regression analyses were performed for an increasing or
decreasing trend with disease incubation on data
obtained in preclinical scrapie and experimental BSE
infection study using a P value of <5% as confidence inter-
val for concluding that the data are unlikely to be sampled
from a population in which the slope is zero. The linearity
of these curves could not be reliably established due to the
small number of samples. The software used for these cal-
culations was Instat Biostatistics from Graph-Pad Soft-
ware, San Diego, CA.
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